Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors
作者:David Harrison、Mark G. Bock、John R. Doedens、Christopher A. Gabel、M. Katharine Holloway、Arwel Lewis、Jane Scanlon、Andrew Sharpe、Iain D. Simpson、Pamela Smolak、Grant Wishart、Alan P. Watt
DOI:10.1021/acsmedchemlett.2c00242
日期:2022.8.11
osteoarthritis, and gout. The discovery of potent and specific NLRP3 inhibitors could reduce the burden of several common morbidities. In this study, we identified a weakly potent triazolopyrimidone hit (1) following an in silico modeling exercise. This was optimized to furnish potent and selective small molecule NLRP3 inflammasome inhibitors. Compounds such as NDT-30805 could be useful tool molecules
NLRP3 炎症小体是一种多蛋白复合物,可促进促炎细胞因子白介素-1β (IL-1β) 和 IL-18 响应感染或内源性刺激而激活和释放。它可能被一系列危险信号不当激活,导致多种疾病的慢性、低度炎症,如阿尔茨海默病、帕金森病、骨关节炎和痛风。有效且特异性的 NLRP3 抑制剂的发现可以减轻几种常见疾病的负担。在这项研究中,我们在计算机建模练习后发现了一种弱效的三唑并嘧啶酮 ( 1 ) 。经过优化,可提供有效且选择性的小分子 NLRP3 炎性体抑制剂。NDT-30805等化合物可能是支架跳跃或药效团生成项目的有用工具分子,或用作临床候选药物开发的先导。